Examkin

Soru

Zorluk: ZorImmunologic and Inflammatory Processes

A series of hospitalized patients develop distinct drug-induced immunologic and inflammatory reactions. Match each specific clinical presentation to its precise underlying foundational pathophysiologic mechanism.

  • A 45-year-old man develops fever, diffuse maculopapular rash, and progressive respiratory distress one week after initiating abacavir for HIV infection.Non-covalent binding to the peptide-binding groove of a specific HLA class I molecule, altering self-peptide presentation and triggering a systemic CD8+ T-cell response.
  • A 60-year-old woman develops new-onset myalgias, arthralgias, and pleuritic chest pain after six months of hydralazine therapy, with a homogeneously positive ANA.Inhibition of T-cell DNA methylation, leading to altered chromatin structure, disrupted tolerance, and subsequent autoantibody formation against histone proteins.
  • A 35-year-old man receiving intravenous vancomycin for bacteremia rapidly develops marked erythema and pruritus of the face, neck, and upper torso during the infusion.Direct, non-IgE-mediated activation of specific G-protein coupled receptors on tissue mast cells, causing rapid systemic degranulation.
  • A 70-year-old man on a proton pump inhibitor develops progressive acute kidney injury, sterile pyuria with eosinophils, and a mild systemic rash.The offending pharmacologic agent acts as a hapten, binding to endogenous structural proteins to form an immunogenic complex that incites a local delayed-type cellular response.

Cevap

Abacavir hypersensitivity matches with HLA-binding alteration. Hydralazine-induced lupus matches with DNA methylation inhibition. Vancomycin flushing matches with direct mast cell activation. Acute interstitial nephritis matches with hapten-mediated delayed T-cell response.
Each specific clinical scenario reflects a unique, high-yield mechanism of drug-induced immunopathology. Abacavir strictly relies on structural modification of the HLA-B*57:01 groove. Hydralazine induces lupus via epigenetic disruption (DNA hypomethylation) causing loss of central T-cell tolerance. Vancomycin causes direct pharmacologic (non-IgE) mast cell degranulation. Proton pump inhibitors cause AIN by acting as haptens that incite a Type IV cell-mediated response in the kidney.

Adım Adım Çözüm

1
Analyze the abacavir vignette.
Identified as abacavir hypersensitivity syndrome. This requires screening for HLA-B*57:01 because the drug directly alters the HLA-binding groove, activating CD8+ T cells.
Recognizing the exact molecular pathogenesis of severe abacavir toxicity is essential for preventing potentially fatal rechallenge.
2
Analyze the hydralazine vignette.
Identified as drug-induced lupus erythematosus (DILE). Hydralazine acts via inhibition of DNA methylation, leading to anti-histone antibody formation.
Differentiating the mechanism of DILE from idiopathic SLE highlights why specific autoantibodies (anti-histone vs. anti-dsDNA) are formed.
3
Analyze the vancomycin vignette.
Identified as vancomycin flushing syndrome. This is an anaphylactoid reaction driven by direct, IgE-independent mast cell degranulation.
Understanding it is not a true IgE-mediated allergy dictates management (slowing the infusion rate rather than permanent contraindication).
4
Analyze the proton pump inhibitor vignette.
Identified as acute interstitial nephritis (AIN). This is classically a Type IV hypersensitivity where the drug acts as a hapten in the renal interstitium.
AIN requires recognition of a delayed, cell-mediated attack on haptenized renal proteins to justify the use of systemic corticosteroids if drug cessation is insufficient.

Anahtar Kavram

Foundational mechanisms of drug-induced immunopathologies (Type IV hypersensitivity, altered MHC presentation, haptenization, and direct mast cell activation).
Bu soruyu puanla

Konular

Immunologic and Inflammatory Processes

Bu konudan daha fazla soru